Delving into the Latest Updates on Renshen Yangrong Tang with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Ninjin'yoeito, RSYRT decoction

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication

AnemiaAnxiety DisordersDecrease in appetite

Inactive Indication-

Originator Organization

Ohsugi Pharmaceutical Co., Ltd.

Active Organization

Ohsugi Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (22 Aug 1986),

AnemiaAnxiety DisordersDecrease in appetite

Regulation-

Login to view timeline

Ninjin’yoeito (NYT) is widely used clinically for the management of patients with frailty and other multiple symptoms. NYT is often administered with other drugs; however, little information is available on its drug interactions. Previous studies using human liver microsomes have reported that constituents of NYT either inhibit (schisandra fruit, cinnamon bark, glycyrrhiza, and poria sclerotium) or induce (schisandra fruit and glycyrrhiza) CYP3A4 expression. Herein, we conducted in vitro and in vivo studies targeting human CYP3A and mouse CYP3A to elucidate the effects of NYT coadministration with other drugs on hepatic drug metabolism. In an inhibition study using human liver microsomes, NYT showed concentration‐dependent reversible inhibition and time‐dependent inhibition. Furthermore, in an induction study using frozen human hepatocytes, the addition of 0.01–0.1 mg/mL NYT resulted in a concentration‐dependent increase in CYP3A gene expression. Contrarily, no significant changes in CYP3A substrate blood concentrations were observed between untreated mice and mice that received either a single dose of NYT or repeated doses for 15 days. These results demonstrate that NYT has inhibitory and inductive effects on hepatic CYP3A in vitro, but orally administered NYT does not affect drug metabolism mediated by hepatic CYP3A in vivo in the mouse model. Although there is a little information about drug interactions of NYT, this study provides new evidence for that.

01 Nov 2022·Journal of Obstetrics and Gynaecology Research

A quasi‐randomized controlled trial of Ninjin'yoeito for the treatment of postpartum anemia and the prevention of postpartum depression

Article

Author: Nitta, Makoto ; Sugimoto, Chisato ; Kuramoto, Akitaka ; Fukuda, Shigeru ; Higashi, Kenji ; Mitani, Minoru ; Ito, Masaharu ; Kawakami, Sho‐ichi ; Umeki, Michiko ; Shinbori, Yoko

AbstractAimTo study the effect of Ninjin'yoeito (NYT) on postpartum anemia and on the development of postpartum depression (PPD).MethodsIn this prospective, single‐center, open‐label, quasi‐randomized controlled trial, patients with anemia 1–2 days postdelivery were randomized to receive either NYT or an oral iron preparation for 4 weeks. The primary endpoint was the hemoglobin (Hb) level. Secondary endpoints were fatigue (assessed by the numerical rating scale [NRS]) and prevalence of postpartum depressive symptoms, as defined by an Edinburgh postnatal depression scale (EPDS) score ≥9. Hb levels and fatigue were measured before, and 4 weeks after, treatment and the EPDS was measured 4 weeks posttreatment.ResultsOf 1066 participants (NYT group: 532, iron group: 534) 1061 (NYT group: 529, iron group: 532) underwent full analysis. The Hb level increased significantly in both groups (p < 0.001), and there were no significant differences between the groups in terms of the change in Hb levels (NYT: 2.4 ± 0.8 g/dL vs. iron: 2.5 ± 0.7 g/dL, p = 0.098). Fatigue decreased significantly in the NYT group (p < 0.001) but did not change in the iron group, and the difference was significant (p < 0.001). There was a significant difference between the two groups in terms of the prevalence of postpartum depressive symptoms (NYT: 5.7% vs. iron: 9.4%, odds ratio [OR] = 0.58, 95% confidence interval [CI] = 0.36–0.93).ConclusionThe results suggest that NYT improves postpartum anemia and fatigue, and may be able to prevent the development of PPD.

100 Deals associated with Renshen Yangrong Tang

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia	Japan	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Anxiety Disorders	Japan	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Decrease in appetite	Japan	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986